Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Cash & Equivalents (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Cash & Equivalents for 11 consecutive years, with $4578.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 3291.11% to $4578.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4578.0, a 3291.11% increase, with the full-year FY2025 number at $69555.0, up 9614.39% from a year prior.
  • Cash & Equivalents was $4578.0 for Q4 2025 at Regen BioPharma, down from $69555.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $727162.0 in Q3 2021 to a low of $135.0 in Q4 2024.
  • A 5-year average of $118886.3 and a median of $69555.0 in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 99.89% in 2024, then surged 9614.39% in 2025.
  • Regen BioPharma's Cash & Equivalents stood at $353492.0 in 2021, then tumbled by 88.47% to $40741.0 in 2022, then skyrocketed by 205.58% to $124497.0 in 2023, then plummeted by 99.89% to $135.0 in 2024, then surged by 3291.11% to $4578.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Cash & Equivalents are $4578.0 (Q4 2025), $69555.0 (Q3 2025), and $1761.0 (Q2 2025).